E-LIB Suche - Ergebnisse für: González-Calle, V.

1

The genomic profiling of high-risk smoldering myeloma patie..:

Medina-Herrera, A. ; Vazquez, I. ; Cuenca, I....
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

S103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIR..:

Fernandez De Larrea, C. ; González-Calle, V. ; Oliver-Caldés, A....
HemaSphere. 6 (2022) - p. 4-5 , 2022

Link: https://doi.org/10.1097/..

3

P862: SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE I..:

Ortiz De Landazuri, I. ; Oliver-Caldés, A. ; Español-Rego, M....
HemaSphere. 6 (2022) - p. 755-756 , 2022

Link: https://doi.org/10.1097/..

4

Prevention of venous thromboembolism in hematologic neoplas..:

Gonzalez-Porras, J. R. ; Mateo, J. ; Gonzalez-Calle, V....
Clinical and Translational Oncology. 24 (2021) 5 - p. 770-783 , 2021

Link: https://doi.org/10.1007/..

5

Bence Jones proteinuria in smoldering multiple myeloma as a..:

González-Calle, V ; Dávila, J ; Escalante, F...
Leukemia. 30 (2016) 10 - p. 2026-2031 , 2016

Link: https://doi.org/10.1038/..

6

Prognostic value of different echocardiographic and cardiac..:

Hernandez Martos, A ; Eiros Bachiller, R ; Gonzalez Calle, V...
European Heart Journal. 44 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

7

MIPI53. A NEW PROGNOSTIC INDEX FOR MANTLE CELL LYMPHOMA:

Boente, M. Bastos ; Sánchez, M. Alcoceba ; Bailón, A. Navarro...
Hematological Oncology. 41 (2023) S2 - p. 748-748 , 2023

Link: https://doi.org/10.1002/..

8

ESMO-Magnitude of Clinical Benefit Scale for haematological..:

Kiesewetter, B ; Dafni, U ; de Vries, EGE...
https://www.repository.cam.ac.uk/handle/1810/353404. , 2023

Link: https://www.repository.c..

9

ESMO-Magnitude of Clinical Benefit Scale for haematological..:

Kiesewetter, B ; Dafni, U ; de Vries, E G E...
https://research.rug.nl/en/publications/c3a2ce7a-f450-4486-912f-a652cb858835. , 2023

Link: https://hdl.handle.net/1..

10

Monoclonal gammopathy of renal significance (MGRS): Real-wo..:

Gozzetti A ; Guarnieri A ; Zamagni E...
info:eu-repo/semantics/altIdentifier/wos/WOS:000783736300001. , 2022

Link: https://hdl.handle.net/1..

11

P862: SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE I..:

Ortiz De Landazuri, I ; Oliver-Caldés, A ; Español-Rego, M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431324/. , 2022

Link: http://www.ncbi.nlm.nih...

12

International Myeloma Working Group risk stratification mod..:

Mateos M. -V ; Kumar S ; Dimopoulos M. A...
info:eu-repo/semantics/altIdentifier/pmid/33067414. , 2020

Link: http://hdl.handle.net/11..

13

Comparison of next-generation sequencing (NGS) and next-gen..:

Medina, Alejandro ; Puig, N ; Flores-Montero, Juan...
Instituto de Salud Carlos III FI19/00320. , 2020

Link: https://ddd.uab.cat/reco..

14

International Myeloma Working Group risk stratification mod..:

Mateos M. -V ; Kumar S ; Dimopoulos M. A...
info:eu-repo/semantics/altIdentifier/pmid/33067414. , 2020

Link: http://hdl.handle.net/11..

15

Immunoparesis Recovery as Predictor Marker of Progression A..:

González de la Calle, V. ; Sobejano, E. ; Dávila, J....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. S51 , 2015

Link: https://doi.org/10.1016/..